# Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 · $419,732

## Abstract

Abstract
The goal of cancer immunotherapy is to utilize the patient’s immune system to reject the invading “foreign”
tumor. However, the pancreatic cancer microenvironment is characterized by an abundance of
immunosuppressive cells and a dense stroma that prevents infiltration of anti-tumor immune cells.
Electroporation is a technique that has been utilized for decades in the laboratory; electrical voltage is applied
to cells to make holes for delivery of DNA and RNA. Irreversible electroporation (IRE) is a technique now
being used clinically for ablation of localized tumors that cannot be removed surgically (locally advanced
tumors). Our objective is to use IRE as an "in situ vaccine" to help the host recognize foreign tumor proteins
(neoantigens) and generate anti-tumor immune responses that will decrease recurrence rates. We have
utilized mouse models of pancreatic cancer to show that IRE generates anti-tumor immune cells that prevent
growth of new tumors (prophylactic immunity). We hypothesize that combining IRE with agents that augment
the immune response will result in inhibition of established, distant tumors (therapeutic immunity or
“abscopal” effects). In Aim 1, we will use mouse models to compare the effects of IRE to radiation therapy
(XRT), as this is the most relevant clinical comparator. Both methods are used clinically for the ablation
(killing) of locally advanced pancreatic cancer but have been shown stimulate systemic immune responses in
preclinical models. We hypothesize that IRE will induce stronger immune responses because XRT causes
fibrosis (scarring) that will inhibit immune cell infiltration. In Aim 2, we will combine local ablation with local
delivery of agents that stimulate the innate immune system in mouse models of metastatic pancreatic cancer.
In Aim 3, we will use a novel model in which human tumors and their associated immune cells are implanted
into immunocompromised mice in order to create a “humanized” immune system. We will use this model to
study the effects of IRE on human tumors. We have assembled a multi-disciplinary team that encompasses
broad expertise in IRE, mouse tumor models, stromal biology, immunotherapy, clinical trials, and clinical care
of patients with pancreatic cancer. We envision that the combination of IRE with immunotherapy will be first
beneficial to patients with locally advanced pancreatic cancer. However, if effective, this approach may also
be beneficial to patients with metastatic disease. Since the IRE technique is already in use clinically, a
clinical trial in which one or more of the agents to be studied is delivered during or after IRE as adjuvant
therapy would likely be feasible in the near future. We will use data from the proposed research to design
such a study.

## Key facts

- **NIH application ID:** 10154535
- **Project number:** 1R01CA254268-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Rebekah White
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $419,732
- **Award type:** 1
- **Project period:** 2021-01-20 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10154535

## Citation

> US National Institutes of Health, RePORTER application 10154535, Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer (1R01CA254268-01A1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10154535. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*